ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
NEW YORK, Jan. 11, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Interim Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis Hotel in San Francisco, CA. The presentation is scheduled to take place on Thursday, January 14, 2016 at 9:00 PST. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the Company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has a pre-clinical program to develop IRAK4 inhibitors, as well as an antibody research program to develop anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.
TGTX - G
CONTACT: Jenna Bosco Director- Investor Relations TG Therapeutics, Inc. Telephone: 212.554.4351 Email: [email protected]
